澳门老奇人论坛

Meeting Coverage >

ESMO

ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer

Adjuvant alectinib reduces disease-free survival hazard by 76%

Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers

Still some unanswered questions about benefit over other drug regimens, expert says

Randomized Trial Backs HIF-2a Inhibition in Advanced RCC

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer

PFS doubled and OS improved, driven by mismatch repair-deficient disease

Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer

Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy

Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer

Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care

New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions

Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses

'Practice-Changing' Data in Locally Advanced Cervical Cancer

Strategies involving immunotherapy, induction chemo move the needle for first time in decades

RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC

Two randomized studies demonstrate significantly improved PFS against standard regimens

Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer

Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy

Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond

Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation

Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer

Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial

Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years

And early ctDNA reductions correlated with survival

Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer

But label update planned after potential harm observed in PD-L1-negative subgroup

Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer

But access, cost, and tolerability may favor the latter option, said researcher

Potential Practice-Changer for Refractory Metastatic Colon Cancer

Significant survival gain with fruquintinib in patients with heavily pretreated disease

Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer

"Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need

Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases

However, no benefit seen with short-term hormone therapy versus radiotherapy alone

Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma

Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy

KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC

"New second-line standard" in KRAS G12C-mutant disease, says study investigator

Triplet in First-Line Kidney Cancer Thwarts Disease Progression

Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone

Survival Bump in Unfit NSCLC With First-Line Immunotherapy

Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets

Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma

Pathologic complete responses seen in 63% of patients in phase II data

Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma

Studies appear to contradict benefit previously shown with pembrolizumab in this setting

Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib

About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists

'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO

Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95%

Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option

More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1

Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer

Post hoc data point to possible benefit in patients with higher PD-L1 levels

Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC

Study also shed lights on what may lead to lung cancer in never smokers

'Potential New Standard' for Progressing Desmoid Tumors

Risk of disease progression or death reduced by 71% with oral gamma secretase inhibitor

Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer

No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo

Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials

Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib

Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer

A closer look at why PARP inhibitor's third-line indication was withdrawn

Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancer

Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing

Checkpoint Inhibitors Whiff in Head and Neck Cancer Trials

Avelumab, nivolumab-ipilimumab, pembrolizumab miss endpoints in separate studies

Survey Says: Support Is Lacking for Cancer's Lingering Effects

Survivors report dissatisfaction with long-term support

Angiogenesis Inhibitor Slows Extrapancreatic Neuroendocrine Tumors

Almost 7-month increase in median PFS with addition of axitinib to endocrine therapy

Transarterial Radioembolization Slows Progression of CRC With Liver Mets

Small increase in median PFS when combined with second-line chemotherapy

Androgen-Targeting Combos Show Promise in Prostate Cancer

Trials extend survival in hormone-sensitive disease

Bifunctional Protein Shows Promise in HPV-Related Cancers

Objective responses in 28% of pretreated patients, durable in most cases

1